单核细胞趋化蛋白-1及其受体在肝纤维化进程中的作用  

Role of monocyte chemoattractant protein 1 and its receptor in the progression of liver fibrosis

作　　者：郭悦承 陆伦根[1] GUO Yuecheng;LU Lungen(Department of Gastroenterology, Shanghai General Hospital, Shanghai 200080, China)

机构地区：[1]上海市第一人民医院消化科

出　　处：《临床肝胆病杂志》2019年第12期2793-2795,共3页Journal of Clinical Hepatology

摘　　要：肝纤维化是慢性肝损伤共有的可逆性病理改变,有进展为肝硬化、肝衰竭、门静脉高压的可能。近年来,多项研究指出,肝纤维化患者趋化因子谱发生显著变化,并且与肝纤维化的进展密切相关。单核细胞趋化蛋白-1(MCP-1)属于CC趋化因子家族,在肝纤维化进程中可发挥激活、募集、迁移炎症细胞的作用,并可能参与肝星状细胞(HSC)的激活、胰岛素抵抗(IR)的形成以及肝细胞癌(HCC)的进展。主要介绍了MCP-1及CC趋化因子受体(CCR)2在肝纤维化发展中的可能作用以及相关疗法的最新进展。Liver fibrosis is a common reversible pathological change in chronic liver injury and may progress to liver cirrhosis,liver failure,and portal hypertension.In recent years,several studies have shown a significant change in chemokine profiles in patients with liver fibrosis,which is closely associated with the progression of liver fibrosis.Monocyte chemoattractant protein 1(MCP-1)belongs to the family of CC chemokines and can induce the activation,recruitment,and migration of inflammatory cells during liver fibrosis.MCP-1 may be involved in the activation of hepatic stellate cells,the development of insulin resistance,and the progression to hepatocellular carcinoma.This article mainly reviews the potential role of MCP-1 and CC chemokine receptor in the progression of liver fibrosis and related therapies.

关 键 词：单核细胞化学吸引蛋白质类 受体 CCR2 肝硬化 巨噬细胞 

分 类 号：R575.2[医药卫生—消化系统]